Immune Response to SARS-CoV-2 Vaccine and Following Breakthrough Omicron Infection in an Autoimmune Patient with Hashimoto's Thyroiditis, Pernicious Anemia, and Chronic Atrophic Autoimmune Gastritis: A Case Report.

Emily Cluff, Lorenza Bellusci, Hana Golding, Surender Khurana

Abstract readCase Reports

In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily CluffCenter for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.

Lorenza BellusciCenter for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.ORCID 0000-0001-9945-1706

Hana GoldingCenter for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.

Surender KhuranaCenter for Biologics Evaluation and Research (CBER), Division of Viral Products, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA.

Funding

United States Food and Drug Administration Medical Countermeasures Initiative (MCMi) grant #OCET 2021-1565

6 · The paper itself

Abstract

In healthy adults, hybrid immunity induced by prior SARS-CoV-2 infection followed by two doses of mRNA vaccination provide protection against symptomatic SARS-CoV-2 infection. However, the role of hybrid immunity in autoimmune patients against Omicron is not well documented. Here, we report a young autoimmune patient with prior infection and two doses of mRNA-1273 vaccination who was exposed to Omicron and developed a symptomatic disease. Prior to Omicron infection, the patient had strong neutralizing antibody titers against the vaccine strain, but no neutralization of Omicron. Post Omicron infection, high neutralizing titers against Omicron were observed. Furthermore, enhanced neutralizing antibody titers against other variants of concern-Alpha, Beta, Gamma, and Delta-were observed, suggesting an expansion of cross-reactive memory B-cell response by the SARS-CoV-2 Omicron infection. Autoimmune patients may require careful monitoring of immune function over time to optimize booster vaccine administration.

Indexed as

autoimmunebreakthroughCOVID-19Hashimoto’smRNAneutralizationOmicronSARS-CoV-2vaccine

Identifiers

PMID35335082

DOI10.3390/vaccines10030450

PMCPMC8949984

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.